Atopic dermatitis - Phase 2 trials of NPI 32101, silver Rx nanocrystals, in a cream formulation
A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of Two Concentrations of Nanocrystalline Silver Cream Applied Twice Daily in Adults with Mild to Moderate Atopic Dermatitis.
This double-blind, randomized, placebo-controlled study in 224 adult patients with mild to moderate symptoms of atopic dermatitis, involved 23 clinical sites across the United States. Patients were treated twice daily for a six-week period with one of two concentrations of NPI 32101 0.5% and 1.0% in a cream formulation or with the vehicle alone. The purpose of the study was to evaluate the safety and efficacy of topical NPI 32101 in improving the signs and symptoms of atopic dermatitis. For results of the trial click here.
An Open-Label, Treatment Continuation Study of 1% Nanocrystalline Silver Cream (NPI 32101) Applied Twice Daily in Adults with Atopic Dermatitis Who Previously Completed a Double-Blind, Placebo-Controlled Study of NPI 32101.
Results of this study are expected in 2005.